Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo Corporation is a healthcare business that intends to improve the quality of life of its customers. I assumed that management will try to expand through new product categories, and will successfully maintain its leading position in technological innovation.

Masimo: Healthcare Data Analysis And Not Expensive

Masimo Corporation shares fell off a cliff early in 2022 amidst the pullback in momentum names and a poorly received deal for Sound. I like the long-term trajectory of the business and gave management the benefit of the doubt, believing it was an overreaction.

Masimo Corporation: Re-Rating Nearing Completion

Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Masimo (MASI) Moves to Strong Buy: Rationale Behind the Upgrade

Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.

Masimo (MASI) PVi Achieves Acceptable Fluid Response in Study

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that Masimo PVi® performed reliably as a predictor of fluid responsiveness in young children undergoing neurosurgery.

New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery

IRVINE, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Masimo and Temple Health are entering into a strategic innovation collaboration focused on hospital automation and telehealth.

Masimo and Temple Health Form Innovation Collaboration with Focus on Hospital Automation and Telehealth Initiatives

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A study has found that noninvasive Masimo PVi® was as effective in guiding fluid management in adult neurosurgical patients as invasive SVV.

New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Adult Neurosurgical Patients

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), a 9% stockholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) today announced that the California State Teachers' Retirement System (CalSTRS) has joined Politan's ongoing legal action against Masimo and its Board of Directors (the “Board”).

CalSTRS Joins Politan Capital Management in Legal Action Against Masimo CEO's Employment Agreement

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the 44th Annual Raymond James Institutional Investors on Tuesday, March 7, 2023 at 11:00 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

Masimo to Present in 44th Annual Raymond James Institutional Investors Conference

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.

Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down

Masimo (MASI) delivered earnings and revenue surprises of 12.82% and 2.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Q4 Earnings and Revenues Beat Estimates

Masimo Corporation (NASDAQ:MASI ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Eli Kammerman - Vice President of Business Development & Investor Relations Joe Kiani - Chairman & Chief Executive Officer Micah Young - Executive Vice President & Chief Financial Officer Conference Call Participants Rick Wise - Stifel Marie Thibault - BTIG Mike Matson - Needham & Company Michael Polark - Wolfe Research Jason Wittes - Loop Capital Markets Jason Bednar - Piper Sandler Jayson Bedford - Raymond James Matt Taylor - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to Masimo's Fourth Quarter and Full Year 2022 Earnings Conference Call. The company's press release is available at www.masimo.com.

Masimo Corporation (MASI) Q4 2022 Earnings Call Transcript

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 31, 2022. Fourth Quarter 2022 Results: Consolidated revenue was $617.0 million, representing 88.3% reported growth. Healthcare revenue was $351.9 million, representing 7.4% reported growth and 10.1% growth on a constant currency basis. Non-healthcare revenue was $265.1 million.

Masimo Reports Fourth Quarter and Full-Year 2022 Financial Results

NEUCHATEL, Switzerland--(BUSINESS WIRE)--In a study, a combination of Masimo ORi™ and SpO2 monitoring reduced hyperoxemia compared to SpO2 alone in patients undergoing laparoscopic surgery.

New Study Evaluates the Utility of Masimo ORi™ in Reducing Hyperoxemia During Laparoscopic Gastrectomy

Apple

A judge for the U.S. ITC ruled in January that Apple violated one of Masimo's patents for using light sensors to gauge blood oxygen levels in smartwatches.

Apple Watch faces potential import ban over patent dispute with Masimo

IRVINE, Calif.--(BUSINESS WIRE)--Vizient has given its Innovative Technology Designation to Masimo Centroid®, a wearable, wireless patient position and activity sensor.

Masimo Centroid® Receives Innovative Technology Designation from Vizient

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Masimo (MASI) to Report a Decline in Earnings: What to Look Out for

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release fourth quarter and FY 2022 financial results for the period ended December 31, 2022, after the market closes on Tuesday, February 28, 2023. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer.

Masimo to Report Fourth Quarter and FY 2022 Financial Results After Market Close on Tuesday, February 28

IRVINE, Calif.--( BUSINESS WIRE )--Masimo (NASDAQ: MASI) today announced the limited market release of Visual Clinical Activity Monitoring (VCAM™), a video analysis system that uses artificial intelligence to help facilitate compliance with hospital hand hygiene protocols. VCAM, which integrates seamlessly with the Masimo Hospital Automation™ platform of solutions, including Masimo Patient SafetyNet™, Replica®, and Root®, is designed to help hospitals and other care facilities optimize protocol adherence, with real-time notifications at the point-of-care about current hand hygiene status and powerful analytics around protocol compliance – with the ultimate goal of helping institutions decrease the incidence of hospital-acquired infections (HAIs).

Masimo Announces the Limited Market Release of Visual Clinical Activity Monitoring (VCAM™)

New Oriental Education & Technology Group

Monolithic Power Systems

Skyworks Solutions

T. Rowe Price Group

Tyler Technologies

Veeva Systems

Nintai Investments: 2022 Annual Review

Masimo's (MASI) patient monitoring devices continue to aid researchers in their assessment of different ventilatory strategies for brain oxygenation during thoracoscopic surgery.

Masimo's (MASI) Patient Monitoring Devices Favored by New Study

NEUCHATEL, Switzerland--( BUSINESS WIRE )--Masimo (NASDAQ: MASI) today announced the findings of a prospective, single-blinded, randomized controlled study published in the Journal of Anesthesia & Intensive Care Medicine in which Dr. Mona Mohamed Mogahed and colleagues at Tanta University in Tanta, Egypt and The King Fahd General Hospital in Jeddah, Saudi Arabia, sought to evaluate the impact of varying ventilation strategies on the cerebral oxygenation of patients undergoing video-assisted thoracoscopic surgery (VATS). To monitor the variety of physiological parameters needed to undertake such an evaluation, they turned to the multi-modal Masimo Root® patient monitoring and connectivity platform, which is designed to allow clinicians to streamline their ability to keep track of numerous modalities, simultaneously, using a single, intuitive monitor. The technologies involved included O3® regional oximetry, capnography with NomoLine® sampling lines, SedLine® brain function monitoring, and multiple rainbow® Pulse CO-Oximetry measurements. Using Root and Masimo monitoring technologies, the researchers were able to determine that maintaining higher end-tidal carbon dioxide (EtCO2) improved baseline regional cerebral oxygenation (rSO2), with impacts on early postoperative cognitive function that included improvements in Aldrete scores and mini mental status exam (MMSE) scores.1

Researchers Harness the Power of Masimo Root®'s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic Surgery

Masimo (MASI) and Royal Philips to create an open ecosystem of medical information using Masimo W1 watch and the latter???s patient monitoring ecosystem to improve home-care.

Masimo (MASI) Expands Partnership with Philips for W1 Watch

Royal Philips

IRVINE, Calif. & ANDOVER, Mass.--( BUSINESS WIRE )--Masimo (NASDAQ: MASI) and Royal Philips (NYSE: PHG, AEX: PHIA) today announced an expansion of their partnership to augment patient monitoring capabilities in home telehealth applications with the Masimo W1™ advanced health tracking watch. The W1 will integrate with Philips's enterprise patient monitoring ecosystem to advance the forefront of telemonitoring and telehealth. The combined innovation, which draws upon the two global medical technology leaders' extensive expertise in monitoring, connectivity, and automation, will be highlighted later this month at Arab Health 2023.

Masimo and Philips Expand Partnership to Improve Telehealth for Patients and Clinicians Around the World with the Masimo W1™ Watch

A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.

News for Masimo Stock (MASI)